Regulation - Pricing, AstraZeneca

Filter

Current filters:

PricingAstraZeneca

Popular Filters

Negative IQWiG view on AstraZeneca’s combo diabetes drug Xigduo

16-05-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

AstraZenecaDiabetesGermanyPharmaceuticalPricingRegulationXigduo

Germany’s IQWiG sees no added benefit of Onglyza as monotherapy

Germany’s IQWiG sees no added benefit of Onglyza as monotherapy

05-12-2013

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products (AMNOG),…

AstraZenecaBristol-Myers SquibbDiabetesEuropeOnglyzaPharmaceuticalPricingRegulation

Report: Tarceva and Iressa favored by European oncologists for NSCLC

Report: Tarceva and Iressa favored by European oncologists for NSCLC

04-11-2013

Oncologists across the top five European countries are prescribing Roche's Tarceva or AstraZeneca's Iressa…

AstraZenecaEuropeIressaOncologyPfizerPharmaceuticalPricingRegulationRocheTarcevaXalkori

Largely negative views from Germany's IQWiG on AstraZeneca's Caprelsa in thyroid cancer

26-06-2013

In a new benefit assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG) has…

AstraZenecaCaprelsaEuropeOncologyPharmaceuticalPricingRegulation

New Zealand to fund AstraZeneca's Brilinta for acute coronary syndromes

10-06-2013

New Zealand's Pharmaceutical Management Agency, PHARMAC, says it has reached an agreement with the local…

Asia-PacificAstraZenecaBrilintaCardio-vascularPharmaceuticalPricingRegulation

UK's NICE backs NHS use of Bristol-Myers/AstraZeneca's Forxiga

30-05-2013

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) today (May 30) issued…

AstraZenecaBristol-Myers SquibbDiabetesEuropeForxigaPharmaceuticalPricingRegulation

IQWiG re-assessments come up with same view for saxagliptin and different for crizotinib

14-05-2013

Under the rules of the German Act on the Reform of the Market for Medicinal Products (AMNOG), the Institute…

AstraZenecaBristol-Myers SquibbcrizotinibDiabetesEuropeKomboglyzeOncologyOnglyzaPfizerPharmaceuticalPricingRegulationsaxagliptinXalkori

Negative NICE guidance for Roche's Avastin and B-MS/AstraZeneca's Forxiga

01-02-2013

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has published draft…

AstraZenecaAvastinBristol-Myers SquibbDiabetesEuropeForxigaOncologyPharmaceuticalPricingRegulationRoche

Scottish Medicines Consortium backs AstraZeneca/B-MS' Forxiga for type 2 diabetes

14-01-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and partner Bristol-Myers Squibb (NYSE: BMY) of the USA…

AstraZenecaBristol-Myers SquibbDiabetesEuropeForxigaPharmaceuticalPricingRegulation

New Zealand agrees to fund Iressa but amends Tarceva use

05-07-2012

New Zealand's pharmaceutical management agency PHARMAC has approved the proposal to fund AstraZeneca's…

Asia-PacificAstraZenecaIressaOncologyPharmaceuticalPricingRegulationRocheTarceva

Germany's IQWiG finds no proof of added benefit for AstraZeneca's Caprelsa in thyroid cancer

05-07-2012

The German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined the added benefit…

AstraZenecaCaprelsaEuropeOncologyPharmaceuticalPricingRegulation

NZ's PHARMAC consults on funding for Iressa and Tarceva

31-05-2012

The Pharmaceutical Management Agency of New Zealand, PHARMAC, is seeking feedback on a proposal to:

Asia-PacificAstraZenecaIressaOncologyPharmaceuticalPricingRegulationRocheTarceva

Nine news Rx drugs added to Australian PBS listings

22-02-2012

Australia’s Federal Minister for Health, Tanya Plibersek, yesterday announced the listing of nine…

Asia-PacificAstraZenecaBrilintaGlaxoSmithKlinePharmaceuticalPricingRegulationZinnat

Mixed NICE views on Faslodex and RoActemra

14-12-2011

There was mixed news this morning from the UK’s National Institute for Health and Clinical Excellence…

Anti-Arthritics/RheumaticsAstraZenecaEuropeFaslodexOncologyPharmaceuticalPricingRegulationRoActemraRoche

UK’s NICE says no to AstraZeneca breast cancer drug Faslodex

10-11-2011

There was negative news this morning for Anglo-Swedish drug major AstraZeneca (LSE: AZN), when the UK’s…

AstraZenecaEuropeFaslodexOncologyPharmaceuticalPricingRegulation

UK’s NICE final guidance backs Takeda’s Mepact and AstraZeneca’s Brilique

26-10-2011

The UK’s National Institute for Health and Clinical Excellence (NICE) issued two final guidances…

AstraZenecaBrilintaBriliqueCardio-vascularEuropeMepactOncologyPharmaceuticalPricingRegulationTakeda Pharmaceuticals

AstraZeneca’s blood thinner Brilinta/Brilique demonstrates cost effectiveness; new Nexium indication filed in Japan

24-10-2011

Data from eight countries shows that using Anglo-Swedish drug major AstraZeneca’s (LSE: AZN) Brilique/Brilinta…

AstraZenecaBrilintaBriliqueCardio-vascularDaiichi SankyoGastro-intestinalsNexiumPharmaceuticalPricingRegulation

AstraZeneca’s Brilique first to be assessed under Germany’s AMNOG, getting positive view

05-10-2011

The German reimbursement body, the Federal Joint Committee (G-BA), has published the Institute for Quality…

AstraZenecaBrilintaBriliqueCardio-vascularEuropePharmaceuticalPricingRegulation

Back to top